Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Tuberculosis

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 76 articles:
HTML format



Single Articles


    April 2020
  1. KESSLER M, Reinig E
    HLH Associated with Disseminated Tuberculosis.
    N Engl J Med. 2020;382:1749.
    PubMed    


  2. TAIT DR, Van Der Meeren O, Hatherill M
    A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. Reply.
    N Engl J Med. 2020;382:1577.
    PubMed    


  3. OTTENHOFF THM
    A Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
    N Engl J Med. 2020;382:1576-1577.
    PubMed    


  4. ZAHEEN A, Bloom BR
    Tuberculosis in 2020 - New Approaches to a Continuing Global Health Crisis.
    N Engl J Med. 2020;382:e26.
    PubMed    


    March 2020
  5. DE JAGER VR, Dawson R, van Niekerk C, Hutchings J, et al
    Telacebec (Q203), a New Antituberculosis Agent.
    N Engl J Med. 2020;382:1280-1281.
    PubMed    


  6. MARKS GB, Nguyen NV, Fox GJ
    Community-wide Screening for Tuberculosis. Reply.
    N Engl J Med. 2020;382:1186.
    PubMed    


  7. KERKHOFF AD, Muyoyeta M, Cattamanchi A
    Community-wide Screening for Tuberculosis.
    N Engl J Med. 2020;382:1185-1186.
    PubMed    


  8. GUPTA A, Montepiedra G, Theron G
    HIV, Pregnancy, and Isoniazid Preventive Therapy. Reply.
    N Engl J Med. 2020;382:1184-1185.
    PubMed    


  9. TIENDREBEOGO T, Anglaret X, Becquet R
    HIV, Pregnancy, and Isoniazid Preventive Therapy.
    N Engl J Med. 2020;382:1184.
    PubMed    


  10. THWAITES G, Nahid P
    Triumph and Tragedy of 21st Century Tuberculosis Drug Development.
    N Engl J Med. 2020;382:959-960.
    PubMed    


  11. CONRADIE F, Diacon AH, Ngubane N, Howell P, et al
    Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
    N Engl J Med. 2020;382:893-902.
    PubMed     Abstract available


    December 2019
  12. ARMSTRONG GL, MacCannell DR, Taylor J, Carleton HA, et al
    Pathogen Genomics in Public Health.
    N Engl J Med. 2019;381:2569-2580.
    PubMed     Abstract available


    October 2019
  13. TAIT DR, Hatherill M, Van Der Meeren O, Ginsberg AM, et al
    Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
    N Engl J Med. 2019 Oct 29. doi: 10.1056/NEJMoa1909953.
    PubMed     Abstract available


  14. MARKS GB, Nguyen NV, Nguyen PTB, Nguyen TA, et al
    Community-wide Screening for Tuberculosis in a High-Prevalence Setting.
    N Engl J Med. 2019;381:1347-1357.
    PubMed     Abstract available


  15. GUPTA A, Montepiedra G, Aaron L, Theron G, et al
    Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
    N Engl J Med. 2019;381:1333-1346.
    PubMed     Abstract available


    September 2019
  16. CHAISSON RE, Ramchandani R, Swindells S
    One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply.
    N Engl J Med. 2019;381:e23.
    PubMed    


  17. STOUT JE, Sterling TR, Horsburgh CR Jr
    One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    N Engl J Med. 2019;381:e23.
    PubMed    


  18. NUNN AJ, Phillips PPJ
    A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.
    N Engl J Med. 2019;381:e22.
    PubMed    


  19. TORNHEIM JA, Udwadia ZF, Gupta A
    A Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019;381:e22.
    PubMed    


  20. MCCAW ZR, Meng Z, Wei LJ
    A Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019;381:e22.
    PubMed    


  21. YOELI E, Rathauser J, Bhanot SP, Kimenye MK, et al
    Digital Health Support in Treatment for Tuberculosis.
    N Engl J Med. 2019;381:986-987.
    PubMed    


    August 2019
  22. LUBKE N, Jensen B, Huttig F, Feldt T, et al
    Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R.
    N Engl J Med. 2019;381:887-889.
    PubMed    


    July 2019
  23. HAVLIR DV, Balzer LB, Charlebois ED, Clark TD, et al
    HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.
    N Engl J Med. 2019;381:219-229.
    PubMed     Abstract available


    June 2019
  24. KHALILI H, O'Shea A, Robbins GK, Zukerberg LR, et al
    Case 19-2019: A 38-Year-Old Woman with Abdominal Pain and Fever.
    N Engl J Med. 2019;380:2461-2470.
    PubMed    


    May 2019
  25. DE VOS M, Ley SD, Wiggins KB, Derendinger B, et al
    Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment.
    N Engl J Med. 2019;380:2178-2180.
    PubMed    


  26. MEINTJES G, Stek C, Maartens G
    Prednisone for Prevention of Paradoxical Tuberculosis-Associated IRIS. Reply.
    N Engl J Med. 2019;380:1781.
    PubMed    


  27. JONES MB
    Prednisone for Prevention of Paradoxical Tuberculosis-Associated IRIS.
    N Engl J Med. 2019;380:1780-1781.
    PubMed    


    March 2019
  28. SAUNDERS MJ, Evans CA
    Ending Tuberculosis through Prevention.
    N Engl J Med. 2019;380:1073-1074.
    PubMed    


  29. SWINDELLS S, Ramchandani R, Gupta A, Benson CA, et al
    One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    N Engl J Med. 2019;380:1001-1011.
    PubMed     Abstract available


  30. NUNN AJ, Phillips PPJ, Meredith SK, Chiang CY, et al
    A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMoa1811867.
    PubMed     Abstract available


  31. CHURCHYARD GJ
    A Short Regimen for Rifampin-Resistant Tuberculosis.
    N Engl J Med. 2019 Mar 13. doi: 10.1056/NEJMe1902904.
    PubMed    


    January 2019
  32. CHEN ST, Cahalane AM, Ryan ET, Foreman RK, et al
    Case 2-2019: A 36-Year-Old Man with Rash, Abdominal Pain, and Lymphadenopathy.
    N Engl J Med. 2019;380:275-283.
    PubMed    


  33. ALSULTAN A, Ashkin D, Peloquin CA
    Bacterial Factors and Relapse after Tuberculosis Therapy.
    N Engl J Med. 2019;380:197.
    PubMed    



  34. Bacterial Factors and Relapse after Tuberculosis Therapy.
    N Engl J Med. 2019;380:197-198.
    PubMed    


    November 2018

  35. H4:IC31 Vaccine or BCG Revaccination for Tuberculosis.
    N Engl J Med. 2018;379:1969.
    PubMed    


  36. MEINTJES G, Stek C, Blumenthal L, Thienemann F, et al
    Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS.
    N Engl J Med. 2018;379:1915-1925.
    PubMed     Abstract available


    September 2018
  37. RUBIN AK, Burk KS, Staller K, Kunitake H, et al
    Case 30-2018: A 66-Year-Old Woman with Chronic Abdominal Pain.
    N Engl J Med. 2018;379:1263-1272.
    PubMed    


  38. COX H, Mizrahi V
    The Coming of Age of Drug-Susceptibility Testing for Tuberculosis.
    N Engl J Med. 2018 Sep 26. doi: 10.1056/NEJMe1811861.
    PubMed    



  39. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
    N Engl J Med. 2018 Sep 26. doi: 10.1056/NEJMoa1800474.
    PubMed     Abstract available


  40. BLOOM BR
    New Promise for Vaccines against Tuberculosis.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMe1812483.
    PubMed    


  41. VAN DER MEEREN O, Hatherill M, Nduba V, Wilkinson RJ, et al
    Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1803484.
    PubMed     Abstract available


  42. MANDAL J, Margaretten M
    Tuberculosis of the Finger.
    N Engl J Med. 2018;379:1161.
    PubMed    


  43. OKAMOTO K, Hatakeyama S
    Tuberculous Peritonitis.
    N Engl J Med. 2018;379:e20.
    PubMed    


    August 2018
  44. COLANGELI R, Jedrey H, Kim S, Connell R, et al
    Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
    N Engl J Med. 2018;379:823-833.
    PubMed     Abstract available


  45. RUBIN EJ
    Of MICs and Men.
    N Engl J Med. 2018;379:882-883.
    PubMed    


  46. MENZIES D, Adjobimey M, Ruslami R, Trajman A, et al
    Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
    N Engl J Med. 2018;379:440-453.
    PubMed     Abstract available


  47. DIALLO T, Adjobimey M, Ruslami R, Trajman A, et al
    Safety and Side Effects of Rifampin versus Isoniazid in Children.
    N Engl J Med. 2018;379:454-463.
    PubMed     Abstract available


    July 2018
  48. NEMES E, Geldenhuys H, Rozot V, Rutkowski KT, et al
    Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
    N Engl J Med. 2018;379:138-149.
    PubMed     Abstract available


    May 2018
  49. YATES TA
    Household-Contact Investigation for Detection of Tuberculosis in Vietnam.
    N Engl J Med. 2018;378:2140-1.
    PubMed    


  50. JAIN Y, Laux T, Patil S
    Household-Contact Investigation for Detection of Tuberculosis in Vietnam.
    N Engl J Med. 2018;378:2140.
    PubMed    



  51. Household-Contact Investigation for Detection of Tuberculosis in Vietnam.
    N Engl J Med. 2018;378:2140-2141.
    PubMed    


  52. FARIA D, Freitas A
    Tuberculous Pericarditis.
    N Engl J Med. 2018;378:e27.
    PubMed    


  53. MCBRIDE JA, Lepak AJ, Dhaliwal G, Saint S, et al
    The Wrong Frame of Mind.
    N Engl J Med. 2018;378:1716-1721.
    PubMed    


    March 2018
  54. THOMPSON RW, Yu H, Dahl DM, Hurtado RM, et al
    Case 10-2018: An 84-Year-Old Man with Painless Unilateral Testicular Swelling.
    N Engl J Med. 2018;378:1233-1240.
    PubMed    


    February 2018
  55. BAO Y, Zheng Y
    Drug-Resistant Miliary Tuberculosis in a Child.
    N Engl J Med. 2018;378:e10.
    PubMed    


    January 2018
  56. FOX GJ, Nhung NV, Sy DN, Hoa NLP, et al
    Household-Contact Investigation for Detection of Tuberculosis in Vietnam.
    N Engl J Med. 2018;378:221-229.
    PubMed     Abstract available


    December 2017
  57. GREENE JA, Loscalzo J
    Putting the Patient Back Together - Social Medicine, Network Medicine, and the Limits of Reductionism.
    N Engl J Med. 2017;377:2493-2499.
    PubMed    


  58. MAITRE T, Aubry A, Veziris N
    Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:2403-4.
    PubMed    



  59. Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:2403-2404.
    PubMed    


    September 2017
  60. BAYER R, Castro KG
    Tuberculosis Elimination in the United States - The Need for Renewed Action.
    N Engl J Med. 2017;377:1109-1111.
    PubMed    


  61. XIE YL, Chakravorty S, Armstrong DT, Hall SL, et al
    Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.
    N Engl J Med. 2017;377:1043-1054.
    PubMed     Abstract available


    August 2017
  62. LETOURNEAU AR, Price MC, Azar MM
    Case 26-2017.
    N Engl J Med. 2017;377:770-778.
    PubMed    


    June 2017
  63. DAVID WS, Bowley MP, Mehan WA Jr, Shin JH, et al
    Case 19-2017 - A 53-Year-Old Woman with Leg Numbness and Weakness.
    N Engl J Med. 2017;376:2471-2481.
    PubMed    


  64. RUBIN EJ
    Reviving a Drug for Tuberculosis?
    N Engl J Med. 2017;376:2292-2294.
    PubMed    


    March 2017
  65. KORATALA A, Bhatti V
    Incidental Finding of Oleothorax.
    N Engl J Med. 2017;376:e21.
    PubMed    


    February 2017
  66. GISMONDI RA, de Souza LF
    Empyema Necessitatis.
    N Engl J Med. 2017;376:e13.
    PubMed    


    January 2017
  67. CASADEVALL A
    Antibodies to Mycobacterium tuberculosis.
    N Engl J Med. 2017;376:283-285.
    PubMed    


  68. SHAH NS, Auld SC, Brust JC, Mathema B, et al
    Transmission of Extensively Drug-Resistant Tuberculosis in South Africa.
    N Engl J Med. 2017;376:243-253.
    PubMed     Abstract available


    December 2016
  69. BRUST JC, Shah NS, Gandhi NR
    More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:2610.
    PubMed    



  70. More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:2609-2611.
    PubMed    


  71. DIACON AH, Van Baelen B, Theeuwes M
    More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:2609-10.
    PubMed    


  72. SALFINGER M, Somoskovi A
    More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:2609.
    PubMed    


    September 2016
  73. GUNTHER G, Lange C, Alexandru S, Altet N, et al
    Treatment Outcomes in Multidrug-Resistant Tuberculosis.
    N Engl J Med. 2016;375:1103-5.
    PubMed    


  74. MASUDA H, Kamada K
    IMAGES IN CLINICAL MEDICINE. Urinary Tract Tuberculosis.
    N Engl J Med. 2016;375:1068.
    PubMed    


  75. ZIGNOL M, Dean AS, Falzon D, van Gemert W, et al
    Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.
    N Engl J Med. 2016;375:1081-9.
    PubMed    


  76. LEGRO RS, Hurtado RM, Kilcoyne A, Roberts DJ, et al
    CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 28-2016: A 31-Year-Old Woman with Infertility.
    N Engl J Med. 2016;375:1069-77.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: